Jianpi Qinghua Formula Alleviates Diabetic Myocardial Injury Through Inhibiting JunB/c-Fos Expression

Abstract

Objective

Diabetic cardiomyopathy (DCM) represents a substantial risk factor for heart failure and increased mortality in individuals afflicted with diabetes mellitus (DM). DCM typically manifests as myocardial fibrosis, myocardial hypertrophy, and impaired left ventricular diastolic function. While the clinical utility of the Jianpi Qinghua (JPQH) formula has been established in treating diabetes and insulin resistance, its potential efficacy in alleviating diabetic cardiomyopathy remains uncertain. This study aims to investigate the impact and underlying molecular mechanisms of the JPQH formula (JPQHF) in ameliorating myocardial injury in nonobese diabetic rats, specifically focusing on apoptosis and inflammation.

Methods

Wistar rats were assigned as the normal control group (CON), while Goto-Kakizaki (GK) rats were randomly divided into three groups: DM, DM treated with the JPQHF, and DM treated with metformin (MET). Following a 4-week treatment regimen, various biochemical markers related to glucose metabolism, cardiac function, cardiac morphology, and myocardial ultrastructure in GK rats were assessed. RNA sequencing was utilized to analyze differential gene expression and identify potential therapeutic targets. In vitro experiments involved high glucose to induce apoptosis and inflammation in H9c2 cells. Cell viability was evaluated using CCK-8 assay, apoptosis was monitored via flow cytometry, and the production of inflammatory cytokines was measured using quantitative real-time PCR (qPCR) and ELISA. Protein expression levels were determined by Western blotting analysis. The investigation also incorporated the use of MAPK inhibitors to further elucidate the mechanism at both the transcriptional and protein levels.

Results

The JPQHF group exhibited significant reductions in interventricular septal thickness at end-systole (IVSs) and left ventricular internal diameter at end-systole and end-diastole (LVIDs and LVIDd). JPQHF effectively suppressed high glucose-induced activation of IL-1β and caspase 3 in cardiomyocytes. Furthermore, JPQHF downregulated the expression of myocardial JunB/c-Fos, which was upregulated in both diabetic rats and high glucose-treated H9c2 cells.

Conclusion

The JPQH formula holds promise in mitigating diabetic myocardial apoptosis and inflammation in cardiomyocytes by inhibiting JunB/c-Fos expression through suppressing the MAPK (p38 and ERK1/2) pathway.

Keywords

Jianpi Qinghua formula / diabetic cardiomyopathy / AP-1 transcription factor / apoptosis / inflammation

References

[1] DillmannWH. Diabetic Cardiomyopathy. Circ Res, 2019, 124(8): 1160-1162

[2] VecchiéA, MontecuccoF, CarboneF, et al.. Diabetes and Vascular Disease: Is It All About Glycemia. Curr Pharm Des, 2019, 25(29): 3112-3127

[3] Lorenzo-AlmorósA, Cepeda-RodrigoJM, LorenzoÓ. Diabetic cardiomyopathy. Rev Clin Esp (Barc), 2022, 222(2): 100-111

[4] JiaG, Whaley-ConnellA, SowersJR. Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia, 2018, 61(1): 21-28

[5] JiaG, DeMarcoVG, SowersJR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol, 2016, 12(3): 144-153

[6] BuggerH, AbelED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia, 2014, 57(4): 660-671

[7] MurtazaG, VirkH, KhalidM, et al.. Diabetic cardiomyopathy - A comprehensive updated review. Prog Cardiovasc Dis, 2019, 62(4): 315-326

[8] JiaG, HillMA, SowersJR. Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity. Circ Res, 2018, 122(4): 624-638

[9] LiuY, HanX, CaiM, et al.. Jianpi Qinghua Fomula alleviates insulin resistance via restraining of MAPK pathway to suppress inflammation of the small intestine in DIO mice. BMC Complement Med Ther, 2022, 22(1): 129

[10] TianJ, CaiM, JinS, et al.. JianPi-QingHua formula attenuates nonalcoholic fatty liver disease by regulating the AMPK/SIRTI/NF-κB pathway in high-fat-diet-fed C57BL/6 mice. Pharm Biol, 2023, 61(1): 647-656

[11] YinMS, ZhangYC, XuSH, et al.. Puerarin prevents diabetic cardiomyopathy in vivo and in vitro by inhibition of inflammation. J Asian Nat Prod Res, 2019, 21(5): 476-493

[12] BaiYL, HanLL, QianJH, et al.. Molecular Mechanism of Puerarin Against Diabetes and its Complications. Front Pharmacol, 2021, 12: 780419

[13] ChenX, YuJ, ShiJ. Management of Diabetes Mellitus with Puerarin, a Natural Isoflavone From Pueraria lobata. Am J Chin Med, 2018, 46(8): 1771-1789

[14] WangY, LiuH, ZhengM, et al.. Berberine Slows the Progression of Prediabetes to Diabetes in Zucker Diabetic Fatty Rats by Enhancing Intestinal Secretion of Glucagon-Like Peptide-2 and Improving the Gut Microbiota. Front Endocrinol (Lausanne), 2021, 12: 609134

[15] XuX, YiH, WuJ, et al.. Therapeutic effect of berberine on metabolic diseases: Both pharmacological data and clinical evidence. Biomed Pharmacother, 2021, 133: 110984

[16] El-OmarMM, YangZK, PhillipsAO, et al.. Cardiac dysfunction in the Goto-Kakizaki rat. A model of type II diabetes mellitus. Basic Res Cardiol, 2004, 99(2): 133-141

[17] MovassatJ, BailbéD, Lubrano-BerthelierC, et al.. Follow-up of GK rats during prediabetes highlights increased insulin action and fat deposition despite low insulin secretion. Am J Physiol Endocrinol Metab, 2008, 294(1): E168-E175

[18] Korkmaz-IcözS, LehnerA, LiS, et al.. Mild Type 2 Diabetes Mellitus Reduces the Susceptibility of the Heart to Ischemia/Reperfusion Injury: Identification of Underlying Gene Expression Changes. J Diabetes Res, 2015, 2015: 396414

[19] DingY, ZhouY, LingP, et al.. Metformin in cardiovascular diabetology: a focused review of its impact on endothelial function. Theranostics, 2021, 11(19): 9376-9396

[20] YangF, QinY, WangY, et al.. Metformin Inhibits the NLRP3 Inflammasome via AMPK/mTOR-dependent Effects in Diabetic Cardiomyopathy. Int J Biol Sci, 2019, 15(5): 1010-1019

[21] YangZ, WangM, ZhangY, et al.. Metformin Ameliorates Diabetic Cardiomyopathy by Activating the PK2/PKR Pathway. Front Physiol, 2020, 11: 425

[22] LingZC, Hong-LieC, OstensonCG, et al.. Hyperglycemia contributes to impaired insulin response in GK rat islets. Diabetes, 2001, 50(Suppl 1): S108-S112

[23] BeddowSA, SamuelVT. Fasting hyperglycemia in the Goto-Kakizaki rat is dependent on corticosterone: a confounding variable in rodent models of type 2 diabetes. Dis Model Mech, 2012, 5(5): 681-685

[24] Homo-DelarcheF, CalderariS, IrmingerJC, et al.. Islet inflammation and fibrosis in a spontaneous model of type 2 diabetes, the GK rat. Diabetes, 2006, 55(6): 1625-1633

[25] LiM, FangH, HuJ. Apelin-13 ameliorates metabolic and cardiovascular disorders in a rat model of type 2 diabetes with a high-fat diet. Mol Med Rep, 2018, 18(6): 5784-5790

[26] HowarthFC, QureshiMA, SobhyZH, et al.. Structural lesions and changing pattern of expression of genes encoding cardiac muscle proteins are associated with ventricular myocyte dysfunction in type 2 diabetic Goto-Kakizaki rats fed a high-fat diet. Exp Physiol, 2011, 96(8): 765-777

[27] CaiL, LiW, WangG, et al.. Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes, 2002, 51(6): 1938-1948

[28] HanRH, HuangHM, HanH, et al.. Propofol postconditioning ameliorates hypoxia/reoxygenation induced H9c2 cell apoptosis and autophagy via upregulating forkhead transcription factors under hyperglycemia. Mil Med Res, 2021, 8(1): 58

[29] ZevolisE, PhilippouA, MoustogiannisA, et al.. The Effects of Mechanical Loading Variations on the Hypertrophic, Anti-Apoptotic, and Anti-Inflammatory Responses of Differentiated Cardiomyocyte-like H9C2 Cells. Cells, 2022, 11(3): 473

[30] SzkudelskaK, OkuliczM, HertigI, et al.. Resveratrol ameliorates inflammatory and oxidative stress in type 2 diabetic Goto-Kakizaki rats. Biomed Pharmacother, 2020, 125: 110026

[31] RitchieRH, AbelED. Basic Mechanisms of Diabetic Heart Disease. Circ Res, 2020, 126(11): 1501-1525

[32] FanF, PodarK. The Role of AP-1 Transcription Factors in Plasma Cell Biology and Multiple Myeloma Pathophysiology. Cancers (Basel), 2021, 13(10): 2326

[33] ShaulianE, KarinM. AP-1 as a regulator of cell life and death. Nat Cell Biol, 2002, 4(5): E131-E136

[34] PiechaczykM, FarràsR. Regulation and function of JunB in cell proliferation. Biochem Soc Trans, 2008, 36: 864-867 Pt 5

[35] CunhaDA, GurzovEN, NaamaneN, et al.. JunB protects β-cells from lipotoxicity via the XBP1-AKT pathway. Cell Death Differ, 2014, 21(8): 1313-1324

[36] CookSJ, AzizN, McMahonM. The repertoire of fos and jun proteins expressed during the G1 phase of the cell cycle is determined by the duration of mitogen-activated protein kinase activation. Mol Cell Biol, 1999, 19(1): 330-341

[37] BalmannoK, CookSJ. Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells. Oncogene, 1999, 18(20): 3085-3097

[38] TasneemS, LiuB, LiB, et al.. Molecular pharmacology of inflammation: Medicinal plants as anti-inflammatory agents. Pharmacol Res, 2019, 139: 126-140

[39] BerthelootD, LatzE, FranklinBS. Necroptosis, pyroptosis and apoptosis: an intricate game of cell death. Cell Mol Immunol, 2021, 18(5): 1106-1121

[40] MedzhitovR. The spectrum of inflammatory responses. Science, 2021, 374(6571): 1070-1075

[41] GravesDT, LiuR, AlikhaniM, et al.. Diabetes-enhanced inflammation and apoptosis—impact on periodontal pathology. J Dent Res, 2006, 85(1): 15-21

[42] Van OpdenboschN, LamkanfiM. Caspases in Cell Death, Inflammation, and Disease. Immunity, 2019, 50(6): 1352-1364

[43] ArthurJS, LeySC. Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol, 2013, 13(9): 679-692

[44] KimJA, JangHJ, Martinez-LemusLA, et al.. Activation of mTOR/p70S6 kinase by ANG II inhibits insulin-stimulated endothelial nitric oxide synthase and vasodilation. Am J Physiol Endocrinol Metab, 2012, 302(2): E201-E208

[45] PengL, ZhouY, DongL, et al.. TGF-β1 Upregulates the Expression of Triggering Receptor Expressed on Myeloid Cells 1 in Murine Lungs. Sci Rep, 2016, 6: 18946

[46] HuangK, HuangJ, ChenC, et al.. AP-1 regulates sphingosine kinase 1 expression in a positive feedback manner in glomerular mesangial cells exposed to high glucose. Cell Signal, 2014, 26(3): 629-638

[47] KangMI, BakerAR, DextrasCR, et al.. Targeting of Noncanonical Wnt5a Signaling by AP-1 Blocker Dominant-Negative Jun When It Inhibits Skin Carcinogenesis. Genes Cancer, 2012, 3(1): 37-50

[48] XuZ, SunJ, TongQ, et al.. The Role of ERK1/2 in the Development of Diabetic Cardiomyopathy. Int J Mol Sci, 2016, 17(12): 2001

[49] WangS, DingL, JiH, et al.. The Role of p38 MAPK in the Development of Diabetic Cardiomyopathy. Int J Mol Sci, 2016, 17(7): 1037

[50] LavoieH, GagnonJ, TherrienM. ERK signalling: a master regulator of cell behaviour, life and fate. Nat Rev Mol Cell Biol, 2020, 21(10): 607-632

[51] JochumW, PasseguéE, WagnerEF. AP-1 in mouse development and tumorigenesis. Oncogene, 2001, 20(19): 2401-2412

[52] OzanneBW, SpenceHJ, McGarryLC, et al.. Transcription factors control invasion: AP-1 the first among equals. Oncogene, 2007, 26(1): 1-10

[53] WestonCR, WongA, HallJP, et al.. The c-Jun NH2-terminal kinase is essential for epidermal growth factor expression during epidermal morphogenesis. Proc Natl Acad Sci U S A, 2004, 101(39): 14114-14119

[54] JunyanLI, FengT, QingguangC, et al.. Effect of Jianpi Qinghua Recipe on Gene Expression Profile and Signal Pathway of Type 2 Diabetes Mellitus Rats. J Tradit Chin Med (Chinese), 2015, 56(17): 1498-1501